Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences
12.1.2026 18:00:00 CET | Business Wire | Press release
First Interoperable AI Agent Trained on Multimodal Patient Data is Accessible Through Model Context Protocol (MCP), Bringing State-of-the-Art Agentic AI to the Healthcare Industry
Owkin, an AI company on a mission to solve the complexity of biology, today announced that its interoperable Pathology Explorer AI agent will be included in the launch of Claude for Healthcare and Life Sciences (HCLS) by Anthropic. This marks the first time a highly specialized, world-leading biological agent trained primarily on multimodal patient data is accessible through the Model Context Protocol (MCP) to a broad audience of healthcare and life sciences professionals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112836381/en/
Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences.
The collaboration enables seamless integration of Owkin's advanced pathology analysis capabilities into Claude's AI platform, making sophisticated biological intelligence accessible to healthcare organizations, pharmaceutical companies, and research institutions within their Claude workflows, without requiring system overhauls or proprietary process changes.
"I believe this agentic interoperability is the future of biopharma discoveries," said Thomas Clozel, M.D., CEO and co-founder of Owkin. "By making our best-in-class agents trained on patient data from the world's leading hospitals accessible through portals like Claude for HCLS, we're enabling the biggest healthcare organizations to accelerate their research in ways that weren't possible before. This is about putting patient data first when training AI and making that intelligence universally available to cure disease faster."
Pathology Explorer is part of Owkin’s K Pro community of agents for biology. This agent identifies and locates cell and tissue types, enabling spatially-aware analysis of patient tissue images. Using the agent, users can analyze tumors and their microenvironments and study inflammation patterns. Pathology Explorer enables the extraction of biomarkers from digitized pathology images to generate and validate hypotheses through cohort-level survival analysis — a critical capability for accelerating drug discovery, clinical trial design, and development of digital diagnostic tools. The agent leverages proprietary, best-in-class AI models that have been trained on patient histopathology data sourced from Owkin's network spanning over 800 hospitals from 104 healthcare centers, enabling it to deliver high-accuracy analysis.
Owkin MCP Integration Enables Seamless Access
Owkin has developed industry standard MCP encoding specifically designed to allow its proprietary K Pro agents to integrate seamlessly with Claude's interface. Pathology Explorer is the first agent from Owkin's interoperable agentic AI infrastructure for biology to be offered for external integration, demonstrating the company's commitment to building an open, API-first infrastructure that can serve as the universal foundation for advancing drug development.
Claude for Healthcare and Life Sciences is designed to accelerate preclinical R&D (including bioinformatics, protocol development, and literature synthesis), streamline clinical trial operations and data management, and support regulatory affairs and submission preparation. The integration of Owkin's Pathology Explorer extends these capabilities by enabling deep biological reasoning specifically trained on real patient data.
This is the third in a series of major announcements Owkin is unveiling, including agentic infrastructure for biology (Owkin's new interoperable agentic infrastructure for biopharma) and a strategic collaboration with NVIDIA to enhance OwkinZero, Owkin's biological large reasoning model.
About Owkin
Owkin is an AI company with $300 million in funding on a mission to solve the complexity of biology. It is building the first Biological Artificial Super Intelligence (BASI) by combining powerful biological large reasoning models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot, and OwkinZero, Owkin's biological large reasoning model, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster. Owkin has exclusive access to multimodal patient data from more than 800 hospitals collected over a decade and partners with eight of the 10 largest pharmaceutical companies. For more information, visit www.owkin.com.
Owkin Media Kit: https://www.owkin.com/press-kit
View source version on businesswire.com: https://www.businesswire.com/news/home/20260112836381/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Iconic Landmark Danjiang Bridge Opened to Redefine Taiwan18.5.2026 12:02:00 CEST | Press release
The Danjiang Bridge, one of Taiwan’s most significant recent public infrastructure projects, officially opened with a series of large-scale public events, transforming the bridge into a new cultural landmark and civic space. The program featured the “Danjiang Bridge Together Arts Festival,” immersive public activities, and a special performance of Light Chain by Cloud Gate Dance Theatre, symbolizing the integration of architecture, engineering, and the arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517667930/en/ The Danjiang Bridge is an iconic landmark in Taiwan with global recognition. (Photo via Highway Bureau , Motc) Spanning the mouth of the Tamsui River, the bridge serves as both a major transportation project and a recognizable architectural landmark, establishing a new urban symbol for Taiwan. Designed by Zaha Hadid Architects, the project gained international attention throughout its development and was sel
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom